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Summary Introduction
Dilated cardiomyopathy has a prevalence of 36/Inherited cardiomyopathies may arise from mutations
in genes that are normally expressed in both heart and 100,000. It is a signiﬁcant cause of congestive heart
failure (CHF) and the major indication for orthotopicskeletal muscle and therefore may be accompanied by
skeletal muscle weakness. Phenotypically, patients with cardiac transplantation (Codd et al. 1989; Dec and Fus-
ter 1994; Kelly and Strauss 1994). The etiology of di-familial dilated cardiomyopathy (FDC) show enlarge-
ment of all four chambers of the heart and develop lated cardiomyopathy is multifold and includes isch-
emic, immunological, toxic, and genetic causes.symptoms of congestive heart failure. Inherited cardio-
myopathies may also be accompanied by cardiac con- Echocardiographic studies of asymptomatic ﬁrst-de-
gree relatives of individuals with idiopathic dilated car-duction-system defects that affect the atrioventricular
node, resulting in bradycardia. Several different chro- diomyopathy estimate that 20%–30% of idiopathic
dilated cardiomyopathy is familial (Michels et al.mosomal regions have been linked with the develop-
ment of autosomal dominant FDC, but the gene defects 1992). Recent genetic linkage studies have implicated
several different chromosomal loci with the develop-in these disorders remain unknown. We now character-
ize an autosomal dominant disorder involving dilated ment of four-chamber cardiac dilation and CHF, con-
ﬁrming the genetic heterogeneity of familial dilated car-cardiomyopathy, cardiac conduction-system disease,
and adult-onset limb-girdle muscular dystrophy (FDC, diomyopathy (FDC) (Kass et al. 1994; Durand et al.
1995; Krajinovic et al. 1995; Olson and Keating 1996;conduction disease, and myopathy [FDC-CDM]). Ge-
netic linkage was used to exclude regions of the genome Bowles et al. 1996). One difﬁculty in identifying defec-
tive genes in FDC has been the lack of large familiesknown to be linked to dilated cardiomyopathy and
muscular dystrophy phenotypes and to conﬁrm genetic with affected, living members and sufﬁcient power for
genetic linkage studies. Despite this, ﬁve different ge-heterogeneity of these disorders. A genomewide scan
identiﬁed a region on the long arm of chromosome netic loci have been linked to the pathogenesis of au-
tosomal dominant FDC, but the defective genes remain6 that is signiﬁcantly associated with the presence of
myopathy (D6S262; maximum LOD score [Zmax] 4.99 unknown (table 1).
Of the ﬁve loci implicated in FDC, two are associatedat maximum recombination fraction [umax] .00), identi-
fying FDC-CDM as a genetically distinct disease. Hap- with phenotypes that include cardiac conduction defects
in addition to dilated cardiomyopathy. The phenotypeslotype analysis reﬁned the interval containing the ge-
netic defect, to a 3-cM interval between D6S1705 and linked to 1p11-1q11 and 3p22-25 initially manifest with
sinoatrial (SA) or atrioventricular (AV) block, resultingD6S1656. This haplotype analysis excludes a number
of striated muscle–expressed genes present in this re- in slow heart rates and syncope (Graber et al. 1986;
Greenlee et al. 1986; Kass et al. 1994; Olson and Keat-gion, including laminin a2, laminin a4, triadin, and
phospholamban. ing 1996). A subset of the affected individuals develops
four-chamber cardiac dilation and clinical CHF. These
disorders have been designated ‘‘FDC-CD1’’ and ‘‘FDC-
CD2,’’ respectively, to distinguish their phenotypes from
three other disorders that involve FDC without conduc-
tion-system disease (isolated FDC). Three chromosomalReceived June 10, 1997; accepted for publication July 24, 1997.
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Table 1
Genetic Loci Implicated in Autosomal Dominant FDC
Disorder OMIM Number Markers for Zmax Locusa Reference
FDC-CD1 115200 D1S305, D1S303 1p11-1q11 Kass et al. (1994)
FDC-CD2 601154 D3S1263, D3S2303 3p22-25 Olson and Keating (1996)
FDC-CDM D6S262, D6S1040 6q22-23 Present report
FDC 601493 D10S607, D10S201 10q21-23 Bowles et al. (1996)
FDC 601494 D1S414, D1S505 1p32 Durand et al. (1995)
FDC 600884 D9S153, D9S152 9q12-13 Krajinovic et al. (1995)
a Six autosomal regions that have been associated with inherited dilated cardiomyopathy; the ﬁrst three
are linked to dilated cardiomyopathy and conduction-system disease affecting the SA and/or AV nodes,
whereas the second three are linked to isolated dilated cardiomyopathy.
Mutations that cause cardiac dysfunction may also by cardiac dilation that is not hypertrophic. CHF and
symptoms of muscle weakness tend to occur later in theresult in skeletal muscle weakness owing to the expres-
sion of the defective gene in all types of striated muscle. disorder. Genetic linkage analysis was performed and
excluded regions already implicated in dilated cardiomy-Myocyte hypertrophy, myocyte loss, and progressive re-
placement by connective tissue are common histopatho- opathy and muscular dystrophy. A genomewide linkage
approach was used to identify the locus responsible forlogical features seen in both dilated-cardiomyopathy
hearts and dystrophic muscle. However, not all of the this disorder, and signiﬁcant linkage was found at 6q23
(D6S262; Zmax 4.99 at umax Å .00). A number of candi-myopathic syndromes affect both cardiac and skeletal
muscle. For example, limb-girdle muscular dystrophy date genes near the region—laminin a2, laminin a4,
phospholamban, and triadin—are excluded by recombi-(LGMD) type 1A, a dominant disorder that links to the
long arm of chromosome 5, appears to affect only skele- nation events between these genes and FDC-CDM. Hap-
lotype analysis has reﬁned the interval containing thetal muscle (Speer et al. 1992). In contrast, the recently
described LGMD type 1B involves an adult-onset, proxi- FDC-CDM gene to 3 cM between D6S1705 and
D6S1656.mal, progressive muscular dystrophy and a cardiac phe-
notype that involves conduction-system disease affecting
the AV node and, in some patients, four-chamber car- Subjects and Methods
diac dilation with CHF (van der Kooi et al. 1996).
Clinical EvaluationsLGMD type 1B recently has been linked to the same
microsatellite markers as FDC-CD1 (Kass et al. 1994; Clinical history was ascertained on living members
through interviews, examinations, and medical records.van der Kooi et al. 1997). The segregation of LGMD
type 1B and FDC-CD1 with the same markers at 1q11- The affectation status of deceased members was deter-
mined frommedical records or reports from other family1p11 may indicate that these disorders are allelic. The
genes that inﬂuence the development of cardiac versus members. Informed consent was obtained under the ap-
proval of institutional review boards (The Children’sskeletal muscle disease are not known, although it is
clear from analysis of dystrophin, the defective gene in Hospital, The University of Chicago Hospitals, and
Duke University Medical Center), and blood was drawnDuchenne muscular dystrophy and X-linked FDC, that
mutations in a single gene may result in skeletal muscle for DNA analysis. Affectation status was determined
by the presence of any of the following: (1) abnormalweakness, CHF, bradyarrhythmias, or varying combina-
tions of these symptoms (Berko and Swift 1987; Mun- electrocardiography (EKG) showing RBBB or second- or
third-degree heart block, (2) echocardiography showingtoni et al. 1993; Towbin et al. 1993).
In this report, we describe a disorder that includes dilated cardiomyopathy with elevated end-systolic and
end-diastolic diameters and/or reduced ejection fraction,autosomal dominant dilated cardiomyopathy, cardiac
conduction-system disease, and an adult-onset, slowly (3) muscular dystrophy with proximal muscle weakness,
(4) abnormal muscle biopsy with variable ﬁber size andprogressive muscular dystrophy that involves the proxi-
mal musculature (FDC-CDM). Younger affected indi- increased connective tissue, or (5) creatine kinase ele-
vated more than two times normal control values. Unaf-viduals who lack skeletal muscle symptoms may show
conduction defects that include right-bundle-branch fected individuals whose genotyping data were used in
LOD-score calculations were ú25 years of age and hadblock (RBBB) or ﬁrst-degree AV block. As the disease
progresses, high-grade AV block appears accompanied been evaluated by a cardiologist and neurologist.
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Genotyping lizes marker-genotype data on all family members while
retaining the phenotypic data on affected family mem-Genomic DNA was puriﬁed by use of PureGene (Gen-
bers only. Thus, the contribution of the more certaintra Systems) (Miller et al. 1988). Genotyping was per-
phenotypic data to the overall LOD score is evaluated.formed with an Applied Biosystems 377 automated
Multipoint analysis was performed with the FASTLINKDNA sequencer using 4.25% acrylamide (SeaQuate
version of LINKMAP. Marker order and intermarkerDNA sequencing solution; Sooner Scientiﬁc). For ge-
distances were based on existing linkage maps (Genomenomewide linkage, the Weber 8 microsatellite repeat
Database 1996 [Ge´ne´thon March 1996, SGC 1996, ormarkers (Research Genetics) were used. Reactions mix-
Whitehead ContigWC6.15November 1996 maps]). Fortures contained 30 ng of genomic DNA in a 10-ml vol-
multipoint analysis, the number of alleles was reducedume of 50 mM KCl, 10 mM Tris-HCl, pH 8.3, 1.5 mM
without loss of information, and the allele frequenciesMgCl2, 0.001% gelatin, 200 mM each dNTP, and 0.5
were set at 1/n.units of AmpliTaq Gold (Perkin-Elmer Applied Biosys-
tems). Ampliﬁcations were performed in anMJ Research
PTC-100-96 thermocycler at 94C for 10 min, followed Results
by 36 cycles of 55C for 1 min, 72C for 30 s, and 94C
Clinical Findingsfor 25 s, followed by a single extension at 72C for
A summary of the symptoms of the affected members10 min. Typically, four or ﬁve PCR primer pairs were
of the kindred is shown in table 2. History was ob-combined per PCR reaction vessel, with a ﬁnal concen-
tained on 60 members of the pedigree, and 25 weretration of 0.08 mM of each primer. For electrophoretic
identiﬁed as affected, on the basis of the presence ofmultiplexing, an average of 10–12 markers were com-
cardiac conduction defects, cardiomyopathy, and/orbined per lane, according to the recommendations of
muscle weakness (ﬁg. 1). At age 37 years, the probandResearch Genetics. Allele sizes were calculated on the
(IV-29) underwent evaluation for cardiac transplanta-basis of an internal size standard in each lane (Genescan-
tion. He reported symptoms of muscle weakness as350 TAMRA; Perkin-Elmer Applied Biosystems). Allele
early as age 17 years. Symptoms of dyspnea on exertionsizes were analyzed by use of Genescan and Genotyper
had been present since age 25 years. A pacemaker hadsoftware (Perkin-Elmer Applied Biosystems) on a Mac-
been implanted at age 29 years, because of syncopalintosh 7600. Markers not part of the Weber 8 set were
episodes due to complete heart block. Echocardiogra-obtained from Research Genetics and were labeled with
phy revealed increased end-systolic and end-diastolicR110-dCTP (Perkin-Elmer Applied Biosystems) at a ra-
diameters, 4.3 cm and 5.5 cm, respectively, with antio of 1:700 (labeled:unlabeled dCTP). Approximately
estimated ejection fraction of 35%. Biatrial enlarge-1/10th of the PCR product was loaded onto the gels for
ment was also noted. Ventricular-wall thickness wasanalysis.
not increased. At cardiac catheterization, the pulmo-
Linkage Analysis nary-capillary-wedge pressure was found to be elevated
at 20 mm Hg; no evidence of coronary artery diseaseAll genotypes were scored blinded to phenotype. Al-
lele information was entered into Cyrillic (Cherwell Sci- was seen on angiography. The proband suffered ven-
tricular tachycardia and died while awaiting cardiacentiﬁc) and was downloaded for MLINK and ILINK
analysis in FASTLINK 3.0P based on LINKAGE 5.1 tranplantation. The proband’s father died at age 49
years, of CHF and arrhythmia. Two of the proband’s(Lathrop et al. 1984). Two-point linkage analysis was
performed by use of the LINKAGE 5.1 package, on siblings, IV-28 and IV-30, were evaluated by cardiac
echocardiography at ages 34 and 32 years, respectively,SoftWindows 2.0 (Insignia Solutions) on a Power Mac-
intosh 7600 or a Sun Ultra 1. Penetrance was set at and were found to have preserved systolic function, but
they complained of mild dyspnea on exertion. IV-281, and the disease-allele frequency was assumed to be
.000005. This allele frequency was used because there had a 3–5-year history of mild muscle weakness and
had had a pacemaker implanted for complete heartare at least six different loci associated with dilated car-
diomyopathy. Furthermore, the combination of FDC block. Ventricular tachycardia was noted on Holter
monitoring. IV-30 had episodes of paroxysmal atrialand muscular dystrophy is more rare than dilated car-
diomyopathy alone. Allele frequencies were set at equal, ﬁbrillation, elevated serum creatine phosphokinase
(CPK), and an EKG showing diffuse ST-T–wave ab-1/n frequencies, where n is the number of alleles at the
marker locus. After the identiﬁcation of linkage, esti- normalities and preserved intervals. Cardiac catheriza-
tion showed normal coronary arteries. At age 27 years,mates of penetrance and allele frequencies were varied
to assess the robustness of the conclusions. In addition IV-31 complained of mild dyspnea on exertion and had
RBBB on EKG. At age 23 years, IV-32 denied muscleto these analyses, ‘‘affecteds-only’’ or low-penetrance
analyses were performed. This conservative analysis uti- weakness or dyspnea on exertion.
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Table 2
Symptoms in FDC-CDM
Age at Death
Patient DCMa Pacemaker Arrhythmiab CHF Symptom(s)c Muscle Symptom(s)d Muscle Biopsye (years)
I-1 Yes Weakness 54
II-2 Yes Unknown
II-4 Yes 39
II-8 (/)X 2:1 HB Yes 57
I-12 Unknown
II-16 Yes Weakness 63
III-3 (/)X,E,P / HB II–III Weakness D 68
III-4 (/)X,E,P / HB II–III Weakness D Living
III-7 Yes None 29
III-11 (/)X,E,P HB-2 I–II Weakness D Living
III-13 (/)X,E,P I–II Weakness D Living
III-15 (/)X,E,P / HB-3 I–II Weakness D Living
III-20 Yes Weakness Unknown
III-23 Weakness Living
III-27 (/)X,P / HB-3 Yes Weakness D 50
Sudden death
IV-2 / HB Weakness Living
IV-3 / HB Weakness Living
IV-5 / HB Living
IV-12 Weakness Living
IV-15 Increased CPK, Living
calf hypertrophy
IV-24 Sudden death None 25
IV-28 (0)X,E,P / HB-3, VT I–II None Living
IV-29 (/)X,E,P / HB-3, VT III–IV Weakness D 37
Sudden death
IV-30 (0)X,E,P PAF I–II Increased CPK D Living
IV-31 RBBB I–II None Living
a Superscript letters indicate method of ascertainment: X Å x-ray; E Å 2D electrocardiographic evaluation; and P Å physical examination.
Diagnostic criterion/criteria for dilated cardiomyopathy were echocardiography showing increased end-systolic, increased end-diastolic, or
reduced ejection fraction; x-ray showing enlarged heart; and/or physical examination showing laterally displaced point of maximum impulse.
b HB Å heart block by history (details unavailable); HB-2 Å second-degree heart block; HB-3 Å third-degree heart block; VT Å ventricular
tachycardia; PAF Å paroxysmal atrial ﬁbrillation; and RBBB Å right bundle branch block.
c By New York Heart Association heart-failure classiﬁcation, when available.
d Weakness Å weakness in a limb-girdle distribution; and Increased CPK Å more than two to four times normal control levels. All patients
remained ambulatory, except for IV-29, who remained so until immediately prior to his death.
e D Å dystrophic changes apparent on light microscopy.
The clinical phenotype encompassed a spectrum of by mitral, aortic, and tricuspid regurgitation, developed
in the later phases of the illness. Symptoms of CHFseverity that increased with increasing age. The youngest
affected individuals had serum CPK that was elevated varied in age at onset. In the late 3d decade, the proband,
IV-29, and his siblings, IV-28 and IV-30, developedto two to four times that in a normal control, ﬁrst-degree
heart block, or RBBB. Elevation of serum CPK was vari- symptoms consistent with the New York Heart Associa-
tion classiﬁcation of heart failure class I–II. In contrast,ably present and was usually two to four times that in
a normal control. Serum CPK elevation was more likely III-11, III-13 and III-15 did not develop symptoms of
dyspnea on exertion until the 4th or 5th decade. Muscleto be present in males than in females but was not reli-
able as a diagnostic measure, since at least one individual weakness was present in a proximal distribution and
progressed in a pattern similar to that of cardiac involve-with muscle weakness (IV-12) did not have elevated se-
rum CPK. Three individuals had sudden death; one was ment. Facial muscles appeared spared. All affected indi-
viduals remained ambulatory throughout their lifetime.without symptoms of either CHF or muscle weakness
at the time of his death. Four-chamber cardiac enlarge- Muscle biopsies, when available, showed dystrophic ar-
chitecture with variation in ﬁber size, centrally placedment, with no increase in wall thickness, accompanied
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Figure 1 FDC-CDM pedigree used for linkage analysis. A single large pedigree with FDC-CDM was ascertained. Affected members of
the pedigree are denoted by blackened symbols; unaffected members are denoted by unblackened/unshaded symbols; members of the pedigree
who were not of sufﬁcient age to allow determination of their affectation status are denoted by gray-shaded symbols; and asterisks (*) indicate
members on whom DNA analysis was performed. The pedigree is ﬁve generations; the ﬁfth generation is not of sufﬁcient age and has been
excluded. Autosomal dominant inheritance was assumed. No decrease in the age at onset was seen in generations in II–IV, arguing against
genetic anticipation.
nuclei, and increased connective tissue and fat. Cardiac signiﬁcant LOD score was found for D6S1040 (Zmax
4.34 at umax Å .00; table 3). The maximal two-pointbiopsies were unavailable.
Twenty individuals were identiﬁed as unaffected, and LOD score was obtained with D6S262 (Zmax 4.99 at
umax Å .00). Varying the penetrance to as low as .6 still15 were scored as ‘‘phenotype unknown,’’ given their
age (õ25 years). All affected members of the pedigree produced maximal two-point LOD scores ú4.00, for
both D6S262 and D6S1040. Given the remote Frenchdeveloped symptoms at age õ25 years, but few had
symptoms at age õ20 years. The majority of the ﬁfth ancestry of the FDC-CDM pedigree, CEPH allele fre-
quencies were substituted for those of D6S262 andgeneration (not shown) was not of sufﬁcient age to allow
determination of their affectation status and was not D6S457, resulting in negligibly higher two-point LOD
scores (data not shown). Two-point LOD scores calcu-included in LOD-score calculations. The inheritance
pattern of FDC-CDM was consistent with autosomal lated by use of the affected-only analysis yielded Zmax
3.36 and 3.08 at umax Å .00, for D6S262 and D6S1040,dominant transmission. Father-to-son transmission ex-
cluded the X chromosome. The age at onset was similar respectively.
in all generations in the pedigree, arguing against genetic Multipoint analysis was performed with D6S1040,
anticipation. The family was of French Canadian de- D6S262, and D6S457, with intervals set at 0.7 cM. A
scent but has been in the United States for four genera- maximum multipoint LOD score of 6.06 was obtained,
tions. No evidence of consanguinity was present. and the interval from D6S1040 to D6S262 was just as
likely for placement of the disease locus as was the inter-
Linkage Analysis val from D6S262 to D6S457. Haplotype analysis
showed that all affected members of the pedigree carryThe loci previously implicated in dilated cardiomyop-
the same-size allele for D6S1040, D6S262, and D6S457athy and muscular dystrophy were excluded as the cause
(ﬁg. 2). IV-32 carries the affected haplotype yet has notof the genetic defect in FDC-CDM, by LOD-score analy-
manifested disease, presumably because of his age (23ses showing signiﬁcantly negative results (data not
years) at examination for this study. Because of pheno-shown). These regions included markers within and sur-
typic uncertainty, his genotype data set was not includedrounding 1p11, 1q32, 3p22-25, 9q13, 10q21-23, 5q22-
in the LOD-score calculations. Figure 2 shows that ﬁve31, 15q15, 2p13, 13q12, 17q12, 4q12, and 19q13. A
affected members (III-11, III-13, III-15, IV-12, and IV-genomewide scan to identify the locus responsible for
15) most likely reﬂect a single recombination event, oc-FDC-CDM was initiated with use of markers with high
curring during transmission between I-1 to II-8, thatheterozygosity that were 90% tri- and tetranucleotide
involves D6S1705 and markers centromeric torepeats and that were spaced at an average of 9 cM
D6S1705. Similarly, D6S1656 and markers telomeric(Shefﬁeld et al. 1995). These markers offered more accu-
to it show a likely single recombination event havingrate allele typing and improved the reliability of the data.
occurred during transmission from I-1 to II-2 or fromThe markers were multiplexed both for PCR and for
II-2 to III-3. Four affected members (III-3, IV-2, IV-3,electrophoresis, to improve throughput and reduce the
and IV-5) reﬂect this recombination event. These recom-time necessary to identify linkage. Sixty markers, ex-
cluding Ç35% of the genome, were analyzed when a bination events deﬁne the FDC-CDM interval as being
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Table 3
Pairwise LOD Scores Reﬂecting Linkage for FDC-CDM and Markers of Chromosome 6q23
LOD SCORE AT RECOMBINATION FRACTION OF
LOCUS .00 .01 .05 .10 .20 .30 .40 Zmax umax
D6S1705 0 01.01 0.43 0.29 0.32 0.38 0.26 . . . . . .
D6S1040 4.34 4.29 3.94 3.49 2.55 1.57 .65 4.34 0
D6S262 4.99 4.90 4.53 4.04 3.00 1.91 .82 4.99 0
D6S457 3.04 2.98 2.73 2.41 1.73 1.04 .40 3.04 0
D6S1656 0 1.07 1.74 1.85 1.58 1.06 .44 1.85 .10
Figure 2 Haplotype analysis of 6q markers in FDC-CDM pedigree. Shown is the FDC-CDM–pedigree subset used for linkage analysis.
The numbers and symbols correspond to those shown in ﬁgure 1. The markers shown are in the following order: centromere-D6S407, D6S1620,
D6S1705, D6S1040, D6S262, D6S457, D6S1656, D6S270, D6S292-telomere. The interval containing the FDC-CDM gene is from D6S1705
to D6S1656.
from D6S1705 to D6S1656 (ﬁg. 3). According to the the development of cardiomyopathy with conduction
system disease and LGMD. The phenotype in this disor-most recent Ge´ne´thon map, this interval is 3 cM. Physi-
cal-map information from the Whitehead Contig der, FDC-CDM, is strikingly similar to that described
WC6.15 (November 1996) shows a high density of for LGMD type 1B, a disorder that links to the centro-
YACs covering the region and that markers deﬁning mere of chromosome 1 (van der Kooi et al. 1996, 1997),
the FDC-CDM critical interval are contained within a demonstrating genetic heterogeneity of autosomal domi-
minimum of two YACs with an estimated size of 2.5– nant cardiomyopathy and muscular dystrophy. Since
3.0 Mb. Preliminary analysis maps a number of ex- LGMD type 1B may be allelic with FDC-CD1, a disease
pressed sequence tags near or within this interval (data that shows only the cardiac symptoms, it is possible
not shown). that additional FDC-CDM families may exhibit a pure
cardiac phenotype as well. Interestingly, early in their
Discussion clinical course, several members of the FDC-CDM pedi-
gree had only cardiac features of the disease, and oneIn this report, we have identiﬁed, on the long arm of
chromosome 6, a locus that is signiﬁcantly linked with suffered sudden death prior to developing any symptoms
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are hypotonic at birth, and those that are laminin a2
deﬁcient have a particularly poor prognosis, often never
achieving independent ambulation (for review, see
Bo¨nnemann et al. 1996). T2-weighted cranial magnetic-
resonance imaging of laminin a2–deﬁcient CMD pa-
tients showed a high degree of white-matter abnormali-
ties, consistent with the expression of laminin a2 in
peripheral nerve, brain, and striated muscle (Vainzof et
al. 1995). The lack of CNS involvement in the FDC-
CDM kindred and the lack of cardiac involvement in
the dy mouse, a murine model of CMD (Michelson et
al. 1955; Meier and Southard 1970), suggest that these
are genetically different disorders. The exclusion of lam-
inin a2 as the genetic defect in FDC-CDM is further
supported by independent conﬁrmation of the LAMA2
genetic interval, by two different groups (Helbling-
Leclerc et al. 1995b; Naom et al. 1997). The most recent
data place the LAMA2 gene centromeric to D6S1620
(Naom et al. 1997). Within the FDC-CDM pedigree,Figure 3 Ideogram of chromosome 6. The markers used in this
there are recombinants for D6S1620 and D6S1705, ex-study derive from the long arm of chromosome 6. The region of 120–
155 cM, as based on the March 1996 Ge´ne´thon map, is shown. Two- cluding the involvement of the LAMA2 locus in FDC-
point and multipoint linkage analysis identiﬁed the markers D6S1040, CDM. To conﬁrm these data, we performed radiation
D6S262, and D6S457 as being signiﬁcantly associated with the devel- hybrid mapping and independently conﬁrmed the place-
opment of autosomal dominant FDC-CDM. Haplotype analysis show-
ment of the LAMA2 gene centromeric to D6S1620 (dataing recombination events occurring at D6S1705, D6S1620, and
not shown). Laminin a4, triadin, and phospholambanD6S407 excluded the genes centromeric to this region—laminin a2,
laminin a4, phospholamban, and triadin. Recombination events were also map centromeric to D6S1705 and, therefore, are
also seen with D6S270, D6S1656, and D6S292, excluding regions excluded as being the defective gene in FDC-CDM
telomeric to D6S1656. The other markers listed here were also tested (Schuler et al. 1996). However, the presence of two lami-
and were consistent with the recombination events described in the
nin genes in this region may suggest a third, since lami-text. Therefore, the critical region for FDC-CDM is ﬂanked by
nin genes can occur in clusters (for review, see WewerD6S1705 and D6S1656. According to the most recent Ge´ne´thon map,
this interval is 3 cM (137–140 cM). and Engvall 1996). Curiously, laminin genes have also
been mapped in 3p22 and 1q32, two regions implicated
in inherited cardiomyopathy (Durand et al. 1995; Olson
and Keating 1996).of CHF or muscle weakness. Even within a single family,
the phenotype varies, spanning the spectrum of cardio- The genetic heterogeneity that now appears to under-
lie FDC may represent multiple different pathogeneticmyopathic and dystrophic symptoms. The association
of cardiac conduction-system disease with dilated car- forms. However, the identiﬁcation of the defective genes
in these disorders may demonstrate that these apparentlydiomyopathy is now seen in three inherited forms of
dilated cardiomyopathy (FDC-CD1, FDC-CD2, and heterogeneous diseases share similar biochemical path-
ways. The familial hypertrophic cardiomyopathiesFDC-CDM) (Graber et al. 1986; Greenlee et al. 1986).
This degree of conduction-system disease is not charac- (FHC) initially appeared to be genetically diverse (Wat-
kins et al. 1995). It is now known that the multiple lociteristic of all idiopathic dilated cardiomyopathy patients
andmay suggest that patients with dilated cardiomyopa- associated with FHC encode sarcomeric proteins that
interact to form the functional unit of contraction. Simi-thy and heart block should be more closely examined
for familial disease. larly, the muscular dystrophies initially were thought
to be genetically heterogeneous. Mutation analysis hasThe proximity of the laminin a2 gene (LAMA2) to
this interval, as well as its involvement in autosomal shown that these genetically diverse myopathic disorders
arise from defects in genes encoding components of therecessive congenital muscular dystrophy, suggested the
possible involvement of laminin a2 mutations in FDC- dystrophin-glycoprotein complex (for reviews, see
Campbell 1995; Ozawa et al. 1995; Bo¨nnemann et al.CDM, an autosomal dominant disease. Mutations in
laminin a2 (formerly known as ‘‘merosin’’) have been 1996). Genetic analyses of patients and their families
with the myopathic disorders have led to a better under-described in autosomal recessive congenital muscular
dystrophy (CMD; OMIM number 156225 [Helbling- standing of the hypertrophic cardiomyopathies and the
muscular dystrophies, by permitting phenotype:geno-Leclerc et al. 1995a; Nissen et al. 1996]). CMD patients
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pay G, Naom I, Muntoni F, et al (1995b) Readjusting thetype correlations and providing a limited ability to pre-
localization of merosin (laminin a2-chain) deﬁcient congeni-dict prognosis based on mutation data. Furthermore,
tal muscular dystrophy locus on chromosome 6q2. C Rthe identiﬁcation of genes involved in these disorders
Acad Sci III 318:1245–52has allowed mutation analysis of apparently sporadic
Kass S, MacRae C, Graber HL, Sparks EA, McNamara D,forms of the myopathic diseases. Continued studies of
Boudoulas H, Basson CT, et al (1994) A gene defect that
genetic causes of FDC should increase our understand- causes conduction system disease and dilated cardiomyopa-
ing of the myopathic process and should have an impact thy maps to chromosome 1p1-1q1. Nat Genet 7:546–551
on therapy for heart failure and muscle dysfunction. Kelly DP, Strauss AW (1994) Inherited cardiomyopathies. N
Engl J Med 330:913–919
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